Paper - WANFANG MED ONLINE

You Position: Home > Paper

二膦酸盐相关颌骨骨坏死研究进展

( views:187, downloads:102 )

Author:: No author available

Journal Title:: China Medicine

Issue:: 11

DOI:: 10.3760/cma.j.issn.1673-4777.2015.11.045

Key Word:: 二膦酸盐;二膦酸盐相关颌骨骨坏死;危险因素

Abstract：二膦酸盐是一类抗破骨细胞活性药物,已被列为治疗各类良、恶性疾病,如多发性骨髓瘤、恶性肿瘤骨转移、Paget's病等引起骨吸收的标准药物;该药还被用来治疗儿童成骨不全(洛布斯坦氏病)[1].然而,长期大量使用二膦酸盐会带来一系列不良反应,如上消化道反应、低钙血症、继发性甲状腺旁腺功能亢进、股骨干骨折等[2-3].自2003年Marx[4]首次报道该药导致颌骨骨坏死以来,国内外有关二膦酸盐相关性颌骨骨坏死(BRONJ)的报道越来越多[5-7],已引起学者们的关注.BRONJ发病机制尚不清[8],临床观察提示其与药物、局部微创伤等危险因素相关.本文对BRONJ的药物相关性因素、局部因素、系统因素、基因易感性等进行综述.

Reference

[1]陈银巧,金洁.二膦酸盐相关性颌骨坏死[J].2007,(4).
[2]马泽云,王衣祥.二膦酸盐相关颌骨骨坏死发病理论进展[J].2014,(2).
[3]余伯龙,李义凯.使用双膦酸盐类药物的不良反应[J].2011,(1).
[4]郭玉兴,王佃灿,安金刚,等.二膦酸盐颌骨骨髓炎24例临床特点分析[J].2014,(9).
[5]David Simcox,Karan Grover,Roger Godfrey,etc.Jaw Osteonecrosis in Patients Receiving Oral Bisphosphonates Therapy[J].2014,5(17).
[6]Francesca, Marini,Paolo, Tonelli,Loredana, Cavalli,etc.Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.[J].2011,3.
[7]A, Biggin,C F, Munns.Osteogenesis imperfecta: diagnosis and treatment.[J].2014,12(3).
[8]黄伟,曾宪涛,冷卫东,等.双磷酸盐相关性颌骨坏死的循证治疗：附3例报道[J].2013,(3).
[9]Katz J,Gong Y,Salmasinia D,etc.Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.[J].2011,40(6).
[10]Chillon MC,Hernandez MT,Alcoceba M,etc.Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.[J].2008,112(7).
[11]Ristow,O.,Gerngro?,C.,Schwaiger,M.,etc.Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: A possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?[J].2014,140(3).
[12]Marx, R. E..Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic[J].2003,61(9).
[13]Sarasquete ME,Gonzalez M,San Miguel JF,etc.Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.[J].2009,15(6).
[14]Marcus J, Heufelder,Joerg, Hendricks,Torsten, Remmerbach,etc.Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw.[J].2014,117(6).
[15]Hoefert, Sebastian,Schmitz, Inge,Weichert, Frank,etc.Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases[J].2015,19(2).
[16]Yougun, Won,Joon-Ryul, Lim,Young-Hwan, Kim,etc.Atypical femoral fracture combined with osteonecrosis of jaw during osteoporosis treatment with bisphosphonate.[J].2014,21(2).
[17].Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.[J].2009,67(5 Suppl.1).
[18]Tsao,C.,Darby,I.,Ebeling,P.R.,etc.Oral health risk factors for bisphosphonate-associated jaw osteonecrosis[J].2013,71(8).
[19]Otto S,Abu Id MH,Fedele S,etc.Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study.[J].2011,39(4).
[20].Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases.[J].2009,30(6).
[21]Goss A,Stein B,Cheng A,etc.Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.[J].2007,65(3).
[22]Cartsos V,Zavras AI,Palaska PK.Bisphosphonates and time to osteonecrosis development.[J].2009,14(11).
[23]Oduncu,F.S.,Pautke,C.,Otto,S.,etc.Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation[J].2012,35(11).
[24]Freiberger JJ,Padilla-Burgos R,Chhoeu AH,etc.Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series.[J].2007,65(7).
[25]Salvatore L Ruggiero,Thomas B Dodson,John Fantasia,etc.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.[J].2014,72(10).
[26]Magopoulos C,Dimitrakopoulos I,Antoniadis K,etc.Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals.[J].2007,28(3).
[27]Kuebler JF,Engelke W,Kos M,etc.Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk.[J].2010,38(4).
[28]Kyrgidis A,Vahtsevanos K,Koloutsos G,etc.Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.[J].2008,26(28).
[29]Salvatore L, Ruggiero,Thomas B, Dodson,Leon A, Assael,etc.American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update.[J].2009,35(3).
[30]Reichart PA,Boonyapakorn T,Schirmer I,etc.Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.[J].2008,44(9).
[31]Márcio, Diniz-Freitas,José-Luis, López-Cedrún,Jacinto, Fernández-Sanromán,etc.Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain.[J].2012,17(5).
[32]Richard P. Harper,Eugene Fung.Resolution of Bisphosphonate-Associated Osteonecrosis of the Mandible: Possible Application for Intermittent Low-Dose Parathyroid Hormone [rhPTH(1-34)][J].2007,65(3).
[33]Vijay, Kumar,Ashish Kumar, Shahi.Nitrogen containing bisphosphonates associated osteonecrosis of the jaws: A review for past 10 year literature.[J].2014,11(2).
[34]Polidoro,S.,Broccoletti,R.,Campanella,G.,etc.Effects of bisphosphonate treatment on DNA methylation in osteonecrosis of the jaw[J].2013,757(2).
[35]Jacobsen,C.,Zemann,W.,Obwegeser,J.A.,etc.The phosphorous necrosis of the jaws and what can we learn from the past: A comparison of "phossy" and "bisphossy" jaw[J].2014,18(1).
[36]Hanasono,M.M.,Militsakh,O.N.,Richmon,J.D.,etc.Mandibulectomy and free flap reconstruction for bisphosphonate-related osteonecrosis of the jaws[J].2013,139(11).
[37]Zavras,A.I.,Floratos,A.,Nicoletti,P.,etc.Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: The role of RBMS3[J].2012,17(2).
[38]Warneke CL,Adamus A,Gagel RF,etc.Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.[J].2008,23(6).
[39]Migliorati CA,Karayianni A,Boziari P,etc.Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center.[J].2011,112(2).
[40]Wilkinson GS,Kuo YF,Freeman JL,etc.Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis.[J].2007,99(13).
[41]Koka S,Mohla S,Raisz LG,etc.Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.[J].2007,22(10).
[42]Fizazi,K.,Zhou,L.,VanPoznak,C.,etc.Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases[J].2012,23(5).
[43]Rogers MJ,Crockett JC,Monkkonen J,etc.Biochemical and molecular mechanisms of action of bisphosphonates.[J].2011,49(1).
[44]Bedogni A,Nocini PF,Saia G,etc.Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review.[J].2010,68(7).